

Rolf W Sparidans

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4113056/publications.pdf>

Version: 2024-02-01

84
papers

2,029
citations

236925

25
h-index

276875

41
g-index

84
all docs

84
docs citations

84
times ranked

2600
citing authors

#	ARTICLE	IF	CITATIONS
1	Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 319-326.	4.1	171
2	Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. <i>International Journal of Cancer</i> , 2014, 134, 1484-1494.	5.1	127
3	Oral Availability and Brain Penetration of the B-RAF ^{V600E} Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar. <i>Molecular Pharmaceutics</i> , 2012, 9, 3236-3245.	4.6	113
4	Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699). <i>Pharmaceutical Research</i> , 2015, 32, 37-46.	3.5	79
5	Hepatic Clearance of Reactive Glucuronide Metabolites of Diclofenac in the Mouse Is Dependent on Multiple ATP-Binding Cassette Efflux Transporters. <i>Molecular Pharmacology</i> , 2010, 77, 687-694.	2.3	67
6	Liquid chromatography-tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 872, 77-82.	2.3	63
7	Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics. <i>Drug Metabolism and Disposition</i> , 2011, 39, 729-735.	3.3	62
8	Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). <i>Pharmacological Research</i> , 2015, 102, 200-207.	7.1	59
9	Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). <i>Pharmaceutical Research</i> , 2015, 32, 2205-2216.	3.5	53
10	Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. <i>Clinical Cancer Research</i> , 2015, 21, 5100-5109.	7.0	49
11	Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Gene Dosage on Plasma Pharmacokinetics and Brain Accumulation of Dasatinib, Sorafenib, and Sunitinib. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 486-494.	2.5	48
12	Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 4090-4096.	2.3	43
13	Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. <i>Pharmacological Research</i> , 2017, 120, 43-50.	7.1	43
14	Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 791, 227-233.	2.3	40
15	Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 118, 123-131.	2.8	39
16	Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1031, 80-85.	2.3	38
17	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis [®] , Trabectedin [®]), a novel marine anti-cancer drug. <i>Investigational New Drugs</i> , 2006, 24, 3-14.	2.6	36
18	P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450 ^{3A} (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib. <i>International Journal of Cancer</i> , 2018, 143, 2029-2038.	5.1	32

#	ARTICLE	IF	CITATIONS
19	Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 269-276.	2.3	31
20	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice. <i>Pharmacological Research</i> , 2018, 129, 414-423.	7.1	31
21	Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O ⁶ -desmethyl metabolites of erlotinib and gefitinib in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1033-1034, 390-398.	2.3	30
22	Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 1851-1856.	2.3	29
23	P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice. <i>Clinical Cancer Research</i> , 2014, 20, 3133-3145.	7.0	29
24	Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). <i>Pharmacological Research</i> , 2019, 146, 104297.	7.1	29
25	Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 130, 244-263.	2.8	26
26	Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and β -ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 839, 45-53.	2.3	25
27	Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2). <i>Molecular Pharmaceutics</i> , 2017, 14, 3258-3268.	4.6	25
28	P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability. <i>Pharmacological Research</i> , 2018, 137, 47-55.	7.1	25
29	Organic Anion-Transporting Polypeptides 1a/1b Control the Hepatic Uptake of Pravastatin in Mice. <i>Molecular Pharmaceutics</i> , 2012, 9, 2497-2504.	4.6	24
30	Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 905, 150-154.	2.3	23
31	Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells. <i>International Journal of Nanomedicine</i> , 2012, 7, 417.	6.7	22
32	Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma. <i>Biomedical Chromatography</i> , 2014, 28, 1366-1370.	1.7	22
33	Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells. <i>Pharmaceutical Research</i> , 2018, 35, 85.	3.5	22
34	Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 161, 136-143.	2.8	22
35	Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1012-1013, 118-123.	2.3	18
36	Isocratic ion-exchange chromatographic assay for the nucleotide gemcitabine triphosphate in human white blood cells. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 780, 423-430.	2.3	17

#	ARTICLE	IF	CITATIONS
37	Liquid chromatographic assay for the protease inhibitor atazanavir in plasma. <i>Biomedical Chromatography</i> , 2006, 20, 72-76.	1.7	17
38	Dendrimer-Based Macromolecular Conjugate for the Kidney-Directed Delivery of a Multitargeted Sunitinib Analogue. <i>Macromolecular Bioscience</i> , 2012, 12, 93-103.	4.1	17
39	Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 136, 120-130.	4.3	17
40	Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1083, 204-208.	2.3	16
41	Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 905, 137-140.	2.3	15
42	<i>P</i> -Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability. <i>Molecular Pharmaceutics</i> , 2018, 15, 5124-5134.	4.6	15
43	Liquid chromatography-tandem mass spectrometric assay for the nucleoside reverse transcriptase inhibitor emtricitabine in human plasma. <i>Biomedical Chromatography</i> , 2007, 21, 621-627.	1.7	14
44	Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 889-890, 144-147.	2.3	14
45	Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 88, 626-629.	2.8	14
46	OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation. <i>British Journal of Pharmacology</i> , 2020, 177, 3060-3074.	5.4	14
47	Liquid chromatography-tandem mass spectrometric assays for salinomycin in mouse plasma, liver, brain and small intestinal contents and in OptiMEM cell culture medium. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 855, 200-210.	2.3	13
48	The potency of clobetasol propionate: Serum levels of clobetasol propionate and adrenal function during therapy with 0.05% clobetasol propionate in patients with severe atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2012, 23, 16-20.	2.2	13
49	Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 925, 124-128.	2.3	12
50	Quantification of cystine in human renal proximal tubule cells using liquid chromatography-tandem mass spectrometry. <i>Biomedical Chromatography</i> , 2018, 32, e4238.	1.7	12
51	Extrahepatic metabolism of ibrutinib. <i>Investigational New Drugs</i> , 2021, 39, 1-14.	2.6	12
52	Simple high-performance liquid chromatographic assay for melphalan in perfusate, rat liver and tumour tissue. <i>Biomedical Chromatography</i> , 2003, 17, 458-464.	1.7	11
53	Liquid chromatography-tandem mass spectrometric assay for pravastatin and two isomeric metabolites in mouse plasma and tissue homogenates. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2751-2759.	2.3	11
54	Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1023-1024, 24-29.	2.3	11

#	ARTICLE	IF	CITATIONS
55	Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1174, 122718.	2.3	11
56	Liquid chromatography-tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 934, 22-25.	2.3	10
57	Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 88, 216-220.	2.8	10
58	Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1102-1103, 167-172.	2.3	10
59	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice. <i>International Journal of Pharmaceutics</i> , 2019, 556, 172-180.	5.2	10
60	P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554). <i>International Journal of Pharmaceutics</i> , 2020, 573, 118842.	5.2	10
61	Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 895-896, 174-177.	2.3	9
62	Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1110-1111, 116-123.	2.3	9
63	Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1147, 122131.	2.3	8
64	Liquid chromatographic assay for the cyclic depsipeptide aplidine, a new marine antitumor drug, in whole blood using derivatization with trans-4- ϵ^2 -hydrazino-2-stilbazole. <i>Biomedical Chromatography</i> , 2004, 18, 16-20.	1.7	7
65	Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1061-1062, 300-305.	2.3	7
66	Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1144, 122098.	2.3	7
67	Liquid chromatography-tandem mass spectrometric assay for clobetasol propionate in human serum from patients with atopic dermatitis. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2150-2154.	2.3	6
68	ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1173-1182.	4.1	6
69	ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib. <i>Pharmacological Research</i> , 2021, 172, 105850.	7.1	6
70	Chromatographic bioanalytical assays for targeted covalent kinase inhibitors and their metabolites. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1162, 122466.	2.3	6
71	ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability. <i>Pharmaceutics</i> , 2021, 13, 1761.	4.5	6
72	Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1122-1123, 78-82.	2.3	5

#	ARTICLE	IF	CITATIONS
73	A robust, accurate, sensitive LC-MS/MS method to measure indoxyl sulfate, validated for plasma and kidney cells. <i>Biomedical Chromatography</i> , 2022, 36, .	1.7	5
74	Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 107, 403-408.	2.8	4
75	Bioanalysis of erlotinib, its O-demethylated metabolites OSI-413 and OSI-420, and other metabolites by liquid chromatography-tandem mass spectrometry with additional ion mobility identification. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1166, 122554.	2.3	4
76	ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability. <i>Pharmacological Research</i> , 2022, 178, 106137.	7.1	4
77	Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N+glucuronide in plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 895-896, 169-173.	2.3	2
78	Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 92, 144-148.	2.8	2
79	P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO). <i>Pharmaceuticals</i> , 2021, 14, 1087.	3.8	2
80	Liquid chromatographic assay for the non-peptidic protease inhibitor tipranavir in plasma. <i>Biomedical Chromatography</i> , 2006, 20, 671-673.	1.7	1
81	Liquid chromatographic assay with fluorescence detection to determine ajmaline in serum from patients with suspected Brugada syndrome. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2168-2172.	2.3	1
82	Development and validation of an LC-MS/MS assay for the quantification of cintirorgon (LYC-55716) in mouse plasma and tissue homogenates. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 207, 114421.	2.8	1
83	MO622IMPAIRED PROTEIN-BOUND UREMIC TOXIN EXCRETION SUGGESTS TUBULAR DYSFUNCTION IN DIABETIC NEPHROPATHY. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
84	Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinib. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 170, 197-207.	4.3	0